Hollister K - Search Results

1

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.

Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Wang H, et al. Among authors: hollister k. Mol Cell. 1999 May;3(5):543-53. doi: 10.1016/s1097-2765(00)80348-2. Mol Cell. 1999. PMID: 10360171

2

A structural model of the constitutive androstane receptor defines novel interactions that mediate ligand-independent activity.

Dussault I, Lin M, Hollister K, Fan M, Termini J, Sherman MA, Forman BM. Dussault I, et al. Among authors: hollister k. Mol Cell Biol. 2002 Aug;22(15):5270-80. doi: 10.1128/mcb.22.15.5270-5280.2002. Mol Cell Biol. 2002. PMID: 12101224 Free PMC article.

3

Identification of gene-selective modulators of the bile acid receptor FXR.

Dussault I, Beard R, Lin M, Hollister K, Chen J, Xiao JH, Chandraratna R, Forman BM. Dussault I, et al. Among authors: hollister k. J Biol Chem. 2003 Feb 28;278(9):7027-33. doi: 10.1074/jbc.M209863200. Epub 2002 Dec 19. J Biol Chem. 2003. PMID: 12496277

4

Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR.

Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. Dussault I, et al. Among authors: hollister k. J Biol Chem. 2001 Sep 7;276(36):33309-12. doi: 10.1074/jbc.C100375200. Epub 2001 Jul 20. J Biol Chem. 2001. PMID: 11466304

5

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis.

Puig L, Lomaga M, Hollister K, Dutronc Y, Berggren L, van de Kerkhof PCM. Puig L, et al. Among authors: hollister k. Acta Derm Venereol. 2020 Dec 9;100(19):adv00344. doi: 10.2340/00015555-3700. Acta Derm Venereol. 2020. PMID: 33236124 Free article.

6

The method history report: an adaptable tool for communicating immunogenicity assay development and validation.

Hollister K, Nguyen HT, Bishop JL, Cramer JW, Bivi N, Gardner MA, Konrad RJ, Hodsdon ME. Hollister K, et al. Bioanalysis. 2020 Nov;12(22):1597-1605. doi: 10.4155/bio-2020-0234. Epub 2020 Nov 6. Bioanalysis. 2020. PMID: 33156693

7

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Langley RGB, et al. Among authors: hollister k. Qual Life Res. 2020 Feb;29(2):369-380. doi: 10.1007/s11136-019-02296-5. Epub 2019 Oct 26. Qual Life Res. 2020. PMID: 31655974 Clinical Trial.

8

J-Pouch Prolapse as a Late Complication of Restorative Proctocolectomy.

Simon R, Hollister K, Stanley JD, Lorenzo-Rivero S. Simon R, et al. Among authors: hollister k. Am Surg. 2018 Sep 1;84(9):e383-e384. Am Surg. 2018. PMID: 30454506 No abstract available.

9

Levels of circulating follicular helper T cells, T helper 1 cells, and the prognostic significance of soluble form of CD40 ligand on survival in patients with alcoholic cirrhosis.

Hollister K, Kusumanchi P, Ross RA, Chandler K, Oshodi A, Heathers L, Teagarden S, Wang L, Dent AL, Liangpunsakul S. Hollister K, et al. Liver Res. 2018 Mar;2(1):52-59. doi: 10.1016/j.livres.2018.02.001. Epub 2018 Feb 22. Liver Res. 2018. PMID: 30221017 Free PMC article.

10

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.

Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, Dossenbach M, Hollister K, Reich K. Paul C, et al. Among authors: hollister k. J Am Acad Dermatol. 2019 Jan;80(1):70-79.e3. doi: 10.1016/j.jaad.2018.06.039. Epub 2018 Jun 30. J Am Acad Dermatol. 2019. PMID: 29969700 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results